3-(3′-adamantan-1-yl-4′-cyanomethoxybiphenyl-4-yl)acrylic acid | 1232886-50-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 3-(3′-adamantan-1-yl-4′-cyanomethoxybiphenyl-4-yl)acrylic acid
• 英文别名: ST5741；(E)-3-(3'-adamantan-1-yl-4'-cyanomethoxybiphenyl-4-yl)acrylic acid；(E)-3-(3'-Adamantan-1-yl-4'-cyanomethoxybiphenyl-4-yl)-acrylic acid；(E)-3-[4-[3-(1-adamantyl)-4-(cyanomethoxy)phenyl]phenyl]prop-2-enoic acid
• CAS: 1232886-50-8
• 化学式: C₂₇H₂₇NO₃
• 分子量: 413.516
• InChiKey: ZGTOYYQZDLCJFD-FPYGCLRLSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  6.7
• 重原子数：
  31
• 可旋转键数：
  6
• 环数：
  6.0
• sp3杂化的碳原子比例：
  0.41
• 拓扑面积：
  70.3
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3-(3′-adamantan-1-yl-4′-cyanomethoxybiphenyl-4-yl)acrylic acid 在 1-羟基苯并三唑 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 盐酸羟胺 、 三乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 28.0h， 以33%的产率得到3-(3'-adamantan-1-yl-4'-cyanomethoxybiphenyl-4-yl)-N-hydroxyacrylamide
  参考文献：
  名称：

  Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors

  摘要：

  To investigate the influence of the adamantyl group on the biological properties of known HDAC inhibitors with a 4-phenylcinnamic skeleton, a series of compounds having the adamantyl moiety in the cap structure were synthesized and compared to the corresponding hydroxamic acids lacking this group. An unexpected finding was the substantial reduction of inhibitory activity toward the tested enzymes, in particular HDAC6, following the introduction of the adamantyl group. In spite of the reduced ability to function as HDAC inhibitors, the compounds containing the adamantyl moiety still retained a good efficacy as antiproliferative and proapoptotic agents. A selected compound (2c; ST3056) of this series exhibited an appreciable antitumor activity against the colon carcinoma xenograft HCT116. (c) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.04.021
• 作为产物：
  描述：

  3-(金刚烷-1-基)-4'-溴-[1,1'-联苯]-4-醇 在 lithium hydroxide monohydrate 、 palladium diacetate 、 potassium carbonate 、 三乙胺 、 三(邻甲基苯基)磷 、 potassium iodide 作用下， 以 四氢呋喃 、 水 、 N,N-二甲基甲酰胺 为溶剂， 反应 8.0h， 生成 3-(3′-adamantan-1-yl-4′-cyanomethoxybiphenyl-4-yl)acrylic acid
  参考文献：
  名称：

  Influence of the adamantyl moiety on the activity of biphenylacrylohydroxamic acid-based HDAC inhibitors

  摘要：

  To investigate the influence of the adamantyl group on the biological properties of known HDAC inhibitors with a 4-phenylcinnamic skeleton, a series of compounds having the adamantyl moiety in the cap structure were synthesized and compared to the corresponding hydroxamic acids lacking this group. An unexpected finding was the substantial reduction of inhibitory activity toward the tested enzymes, in particular HDAC6, following the introduction of the adamantyl group. In spite of the reduced ability to function as HDAC inhibitors, the compounds containing the adamantyl moiety still retained a good efficacy as antiproliferative and proapoptotic agents. A selected compound (2c; ST3056) of this series exhibited an appreciable antitumor activity against the colon carcinoma xenograft HCT116. (c) 2014 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2014.04.021

文献信息

• [EN] NEW RETINOID DERIVATIVES ENDOWED WITH CYTOTOXIC AND/OR ANTIANGIOGENIC PROPERTIES<br/>[FR] NOUVEAUX DÉRIVÉS DE RÉTINOÏDES PRÉSENTANT DES PROPRIÉTÉS CYTOTOXIQUES ET/OU ANTI-ANGIOGÈNES
  申请人：SIGMA TAU IND FARMACEUTI

  公开号：WO2010072727A1

  公开（公告）日：2010-07-01

  The present invention relates to new retinoid derivatives of Formula (I), and to pharmaceutical compositions containing them for the treatment of patients affected by pathologies such as arthritic conditions, tumours, metastatic cancer, diabetic retinopathy, psoriasis, chronic inflammatory diseases or atherosclerosis.

  本发明涉及公式(I)的新视黄醇衍生物，以及含有它们的药物组合物，用于治疗患有关节炎、肿瘤、转移性癌症、糖尿病性视网膜病变、银屑病、慢性炎症性疾病或动脉粥样硬化等病症的患者。
• RETINOID DERIVATIVES ENDOWED WITH CYTOTOXIC AND/OR ANTIANGIOGENIC PROPERTIES
  申请人：Cabri Walter

  公开号：US20110312965A1

  公开（公告）日：2011-12-22

  The present invention relates to new retinoid derivatives of formula I and to pharmaceutical compositions containing them for the treatment of patients affected by pathologies such as arthritic conditions, tumours, metastatic cancer, diabetic retinopathy, psoriasis, chronic inflammatory diseases or atherosclerosis.

  本发明涉及公式I的新视黄醇衍生物和含有这些衍生物的药物组合物，用于治疗患有关节炎、肿瘤、转移性癌症、糖尿病性视网膜病变、银屑病、慢性炎症性疾病或动脉粥样硬化等病理的患者。
• Retinoid derivatives endowed with cytotoxic and/or antiangiogenic properties
  申请人：Cabri Walter

  公开号：US08530517B2

  公开（公告）日：2013-09-10

  The present invention relates to new retinoid derivatives of formula I and to pharmaceutical compositions containing them for the treatment of patients affected by pathologies such as arthritic conditions, tumors, metastatic cancer, diabetic retinopathy, psoriasis, chronic inflammatory diseases or atherosclerosis.

  本发明涉及公式I的新型视黄醇衍生物及其含有的制药组合物，用于治疗患有关节炎、肿瘤、转移性癌症、糖尿病性视网膜病变、牛皮癣、慢性炎症性疾病或动脉粥样硬化病的患者。
• New retinoid derivatives as back-ups of Adarotene
  作者：Giuseppe Giannini、Tiziana Brunetti、Gianfranco Battistuzzi、Domenico Alloatti、Gianandrea Quattrociocchi、Maria Grazia Cima、Lucio Merlini、Sabrina Dallavalle、Raffaella Cincinelli、Raffaella Nannei、Loredana Vesci、Federica Bucci、Rosanna Foderà、Mario Berardino Guglielmi、Claudio Pisano、Walter Cabri

  DOI：10.1016/j.bmc.2012.01.042

  日期：2012.4

  Adarotene belongs to the so-called class of atypical retinoids. The presence of the phenolic hydroxyl group on Adarotene structure allows a rapid O-glucuronidation as a major mechanism of elimination of the drug, favoring a fast excretion of its glucuronide metabolite in the urines. A series of ether, carbamate and ester derivatives was synthesized. All of them were studied and evaluated for their stability at different pH. The cytotoxic activity in vitro on NCI-H460 non-small cell lung carcinoma and A2780 ovarian tumor cell lines was also tested. A potential back-up of Adarotene has been selected to be evaluated in tumor models. (C) 2012 Elsevier Ltd. All rights reserved.
• NEW RETINOID DERIVATIVES ENDOWED WITH CYTOTOXIC AND/OR ANTIANGIOGENIC PROPERTIES
  申请人：SIGMA-TAU Industrie Farmaceutiche Riunite S.p.A.

  公开号：EP2367781A1

  公开（公告）日：2011-09-28